Eupraxia Pharmaceuticals (NASDAQ:EPRX) released new 24-week results from the highest dose cohort of its Phase 1b/2a RESOLVE trial, evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
The data from Cohort 9, which included three patients, demonstrated a mean reduction in the Symptom Diary Index (SDI) of 4 points at 24 weeks.
This result is particularly significant given that a 3-point reduction is the established threshold for clinical remission in EoE, suggesting that the highest dose level provides robust and durable symptom relief.
When looking at the broader trial population, the pooled data from Cohorts 4 through 9 highlighted the sustained efficacy of Eupraxia’s extended-release fluticasone propionate formulation.
Clinical remission was achieved by 59% of patients (13 of 22) at week 12, rising to 76% (13 of 17) at week 24.
Even at the one-year mark, the data remained strong, with 67% of patients (6 of 9) maintaining remission at 52 weeks.
These figures underscore the potential of EP-104GI to provide a long-acting alternative to daily topical steroids, which often suffer from poor patient compliance and localized side effects.
Safety remains a primary differentiator for Eupraxia’s platform.
Across 31 patients and over 220 patient-months of exposure, no serious adverse events (SAEs) were reported.
Crucially, there were no cases of oropharyngeal candidiasis (thrush), a common side effect of traditional swallowed topical steroids.
This suggests that Eupraxia’s "DiffuX" technology is successfully containing the corticosteroid within the esophageal tissue, minimizing the systemic and surface-level exposure that typically leads to fungal infections or adrenal suppression.